OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ALEMG55

Laboratoires Euromedis SA

Medical Equipment, Supplies & DistributionVerified

Laboratoires Euromedis SA has a basic and diluted share count of 2,844,222, indicating no dilution from stock options or convertible securities. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company reported a loss per share of -1.66 EUR and revenue of 58,696,000 EUR in the latest period. These figures suggest a challenging profitability environment, with the company currently operating at a loss. The absence of valuation snapshot data prevents a direct comparison with industry medians for profitability and returns. There is no detailed information on the company's segments or geographic exposure, which limits the ability to assess revenue concentration or diversification. The lack of segmental data also hinders the evaluation of the company's growth trajectory and the contribution of different business lines to overall performance. The company's risk assessment indicates a low dilution risk, but the liquidity risk remains unknown. The absence of balance-sheet inputs and no going-concern language in the source documents suggests that the company's financial health and liquidity position are not transparent. There are no recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial status.

30-day price · ALEMG(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyLaboratoires Euromedis SA
TickerALEMG.PA
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Laboratoires Euromedis SA operates in the Healthcare Services & Equipment sector, specializing in Medical Equipment, Supplies & Distribution.

Classification. The company is classified under the industry of Medical Equipment, Supplies & Distribution with a confidence level of 0.92.

Laboratoires Euromedis SA has a basic and diluted share count of 2,844,222, indicating no dilution from stock options or convertible securities. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company reported a loss per share of -1.66 EUR and revenue of 58,696,000 EUR in the latest period. These figures suggest a challenging profitability environment, with the company currently operating at a loss. The absence of valuation snapshot data prevents a direct comparison with industry medians for profitability and returns. There is no detailed information on the company's segments or geographic exposure, which limits the ability to assess revenue concentration or diversification. The lack of segmental data also hinders the evaluation of the company's growth trajectory and the contribution of different business lines to overall performance. The company's risk assessment indicates a low dilution risk, but the liquidity risk remains unknown. The absence of balance-sheet inputs and no going-concern language in the source documents suggests that the company's financial health and liquidity position are not transparent. There are no recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial status.
Key takeaways
  • The company is currently reporting a loss per share of -1.66 EUR.
  • Revenue for the latest period is 58,696,000 EUR.
  • There is no dilution from stock options or convertible securities.
  • The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs.
  • The company's segments and geographic exposure are not detailed in the provided data.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's current loss per share indicates a negative margin outlook, driven by operational inefficiencies or high costs.
  • **rd_outlook_rationale**: No information is available to assess the outlook for research and development activities.
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$111.9M$6.4M$2.3M$2.0M
FY-3$54.2M-$5.8M-$5.9M-$5.8M
FY-2$34.0M-$14.0M$13.1M
FY-1$36.2M-$6.1M-$6.2M
FY0$40.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$72.7M$41.0M
FY-3$59.9M$34.7M
FY-2$46.3M$22.6M
FY-1$38.8M$16.5M
FY0
PeriodOCFCapExFCFSBC
FY-4$19.2M-$1.8M$2.0M
FY-3-$1.0M-$1.0M-$5.8M
FY-2
FY-1
FY0
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricALEMGActivity
Op margin3.9% medp25 -31.3% · p75 14.4%
Net margin2.4% medp25 -30.5% · p75 11.1%
Gross margin46.7% medp25 28.2% · p75 63.1%
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-4.8% medp25 -11.6% · p75 -2.4%
Debt / equity17.9% medp25 2.7% · p75 52.2%
Observations
IR observations
Last actual EPS-1.66 EUR
Last actual revenue58,696,000 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-02 02:13 UTC#677899e6
Market quoteclose EUR 4.68 · shares 0.00B diluted
no public URL
2026-05-02 02:13 UTC#22b9e6ba
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 07:48 UTCJob: c68e5606